Uvax Bio Preps to Take HIV Vaccine into the Clinic By Mark TerryMay 2, 2023 Uvax Bio, headquartered in Newark, Del., recently published preclinical results in Nature Communications showing the [….]
Uvax Bio Preps to Take HIV Vaccine into the Clinic
Gaithersburg’s Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company’s combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the manuscript is available at bioRxiv.org.